BACKGROUND: Drug interaction studies selecting patients in a real-life setting are scarce, and most studies to date are characterized by a small sample size.
What is already known about this subject
• Simultaneous use of amiodarone is not associated with adverse events in chronic anticoagulation therapy.
• No significant interactions with known polymorphisms that modulate warfarin metabolism were identified for the amiodarone effect.
What this study adds
W arfarin is the most frequently used oral anticoagulant worldwide. It is indicated for the prophylaxis and treatment of venous thromboembolic events, as well as for the prevention of systemic embolism in patients with prosthetic heart valves or atrial fibrillation. The level of anticoagulation with warfarin can be regularly monitored by the international normalized ratio (INR). However, warfarin therapy can be challenging because of its narrow therapeutic range and the wide variation in interindividual response and consequent requirement to vary dosage. 1 Studies have shown that polymorphisms in the CYP2C9 gene affect the rate at which patients metabolize S-warfarin, the most active enantiomer of the drug. 2 Patients carrying c.430C > T (CYP2C9*2) and c.1075A > C (CYP2C9*3) polymorphisms in the CYP2C9 gene metabolize warfarin poorly compared with patients with wild-type genotypes (CYP2C9*1), resulting in the need for lower drug doses. 3, 4 VKORC1 encodes the vitamin K epoxide reductase complex 1, which is the therapeutic target of warfarin. VKORC1 c.1639G > A polymorphism leads to lower protein levels, making it necessary to administer smaller doses of the drug. 5, 6 Amiodarone, a class III antiarrhythmic drug, is frequently used to treat cardiac arrhythmias. This drug can interact with warfarin metabolism by inhibiting CYP2C9 and CYP3A4 isoenzymes. 7 Studies have reported increased anticoagulant effects of warfarin in patients treated simultaneously with amiodarone. [8] [9] [10] [11] Other studies have indicated that interactions are commonly observed at 1 week after administration of these drugs and may increase potentially up to 6 weeks, although significant clinical effects of these interactions were not seen in a number of studies. 7, 12 Drug interaction studies selecting patients in a real-life setting are scarce, and most studies to date are characterized by a small sample size. The main objective of our study was to evaluate the influence of the simultaneous use of amiodarone and warfarin on both warfarin maintenance dose and adverse events in a large patient cohort from a tertiary cardiovascular service.
Predicted Metabolic Phenotypes
According to CYP2C9 Polymorphisms Individuals were divided into distinct predicted phenotypes: extensive metabolizer (EM: wild-type genotypes for the CYP2C9 polymorphisms -*1/*1), intermediate metabolizer (IM: heterozygous genotypes for the loss-of-function CYP2C9 polymorphisms -*1/*2 or *1/*3) and poor metabolizer (PM: mutant homozygous or compound heterozygous genotypes for the loss-of-function CYP2C9 polymorphisms -*2/*2 or *3/*3 or *2/*3).
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INR Protocol
Oral anticoagulant therapy was assessed by the prothrombin time (PT) in an automated coagulometric method. Venous blood samples were collected in tubes containing sodium citrate 3.8%. Plasma was obtained by centrifugation at 3,000 revolutions per minute for 10 minutes in Tcoag Destiny Max equipment with the aid of the kit specific to PT (Tcoag, TriniCLOT, Trinity Biotech, Ireland). The calculation of INR was obtained by the ratio PT of the patient/normal control PT, elevated to the ISI (international sensitivity index). Follow-up of PT for dose adjustment was decided by the physician based on guideline recommendations. 23 
Statistical Analysis
Categorical variables are presented as percentages, while continuous variables are presented as mean ± standard deviation or mean ± standard error of the mean. Chi-square tests were
■■ Methods Patients and Study Design
This retrospective cohort study included 936 patients treated with warfarin for at least 12 months at the Heart Institute (Incor), University of São Paulo, São Paulo, Brazil (September 2011-March 2012). Data regarding current drug use were obtained through a standardized interview with a pharmacist and checked on electronic medical records. Current and past INR values were checked in electronic medical records for the 12 months preceding enrollment. Blood samples were collected to assess current INR and DNA analysis. Patients with chronic liver failure, using other anticoagulant drugs, receiving chemotherapy, or with alcoholism were excluded. The study protocol was approved by the Institutional Ethics Committee (Register Number 0804/10), and written informed consent was obtained from all participants prior to entering the study. Patients were separated in self-declared "racial/color" subgroups according to the criteria used by the Brazilian census, as white, intermediate (meaning brown, pardo in Portuguese), or black. 13, 14 Time in therapeutic range (TTR) was calculated by the Rosendaal method, which uses linear interpolation to assign an INR value to each day between successive observed INR values. 15 The percentage of time during which the interpolated INR values lie between 2.0 and 3.0 (from 0% to 100%) is calculated by dividing the days in range by the total number of days on warfarin. Also, the frequency of INR within target was analyzed.
Warfarin doses were empirically determined by the physicians, who were unaware of the CYP2C9 and VKORC1 genotypes. Achievement of the therapeutic target was defined as having 2 consecutive values of INR between 2.0 and 3.0. Major bleeding was defined mainly as fatal bleeding; intrapericardial bleeding with cardiac tamponade; intracranial bleeding; severe hypotension, or hypovolemic shock caused by bleeding and requiring either vasopressors or surgical intervention; and a decline in hemoglobin of 5.0 grams per deciliter (g/dL) or more after adjusting for red blood cell transfusions. Minor bleeding was classified as any bleeding event requiring medical intervention but not meeting the criteria for major bleeding. Some adverse events were classified as others according to label (skin disorders and hair loss related to warfarin use). 16, 17 Genotyping Genomic DNA was extracted from peripheral blood leukocytes by the standard salting-out method. 18 Genotyping of CYP2C9*2 (c.430C > T, rs1799853) and CYP2C9*3 (c.1075A>C, rs1057910) polymorphisms was detected by a polymerase chain reaction (PCR) followed by a restriction enzyme 19 and VKORC1 3673 (c.1639G > A, rs9923231) by PCR followed by high-resolution melting analysis (Rotor Gene 6000, Qiagen, Courtaboeuf, France), 13, 20 according to the protocol previously described. 
Clinical and Demographic Characteristics According to Simultaneous Use of Amiodarone
performed for comparative analysis of the categorical variables (such as adverse events, frequency of patients with INR ≥ 4.0 or 2.0 ± INR ± 3.0, frequency of patients within the therapeutic target) according to the simultaneous use of amiodarone. The t-test was used for comparing the warfarin dose and the INR/ current dose ratio, according to simultaneous use of amiodarone. The warfarin dose and INR/current dose ratio were assessed in 2 models: model 1, without adjustment, and model 2, adjusted for age, sex, body mass index, "race/color," smoking, and studied polymorphisms. The INR/current dose ratio was obtained from the INR value divided by the daily current dose mean. All statistical analyses were carried out using SPSS software, version 16.0 (SPSS, Inc., Chicago, IL), with the level of significance set at P ≤ 0.05.
■■ Results Clinical and Demographic Characteristics
Clinical and demographic characteristics of the patients are shown in Table 1 . Of the 866 patients (mean age 62.3 ± 13.9), 433 (50.0%) were female. Main indications for treatment with warfarin therapy were atrial fibrillation or flutter, previous cerebrovascular accident, thrombosis or embolus, and use of prosthetic heart valves (excluding mechanical valves) requiring chronic anticoagulation (Table 1) . Of the study patients, 111 (12.8%) were simultaneously taking amiodarone and warfarin for at least 12 months. Mean amiodarone daily dose was 220 milligrams (mg; ± 107 mg) and mean warfarin weekly dose was 28.7 mg (± 14.0 mg). Of the total group, 514 patients (59.4%) were within the therapeutic target (INR between 2.0 and 3.0 in at least 2 consecutive tests, including the current test, in the past 12 months). Average time of anticoagulation of the study patient group was 6.4 ± 5.3 years (minimum = 1 year; maximum = 32 years).
Mean Warfarin Dose, INR/Dose Ratio, Adverse Events, and Therapeutic Target According to Simultaneous Use of Amiodarone Mean warfarin dose was significantly lower in patients who were simultaneously using amiodarone (23.8 ± 11.5 milligrams per week [mg/wk]) compared with other patients (29.6 ± 13.1 mg/wk; P < 0.001), even after adjustment for covariates ( 
Simultaneous Use of Amiodarone Influences Warfarin Maintenance Dose but Is Not Associated with Adverse Events
tests; P = 0.61). Also, the TTR and percentage of INRs within target were not different between patients on amiodarone (59.5 ± 22.5% and 48.8%, respectively) and patients not on amiodarone (61.7 ± 24.6% and 55.3%, respectively; P = 0.43 and P = 0.16, respectively), adjusted for covariates.
INR/current dose ratio was also significantly different among patient groups. Patients taking amiodarone had a higher mean value (0.83 ± 0.04 per mg) compared with patients who did not take amiodarone (0.71 ± 0.02 per mg, P = 0.001), adjusted for covariates (Table 2) .
Interestingly, frequencies of adverse events, major or minor bleedings, and patients with INR ≥ 4 were not different according to amiodarone use (P = 0.40, P = 0.78, and P = 0.59, respectively). A tendency was observed for a higher frequency of patients within the therapeutic range in patients not taking amiodarone (60.5% vs. 51.4%, P = 0.06; Table 2 ).
Analysis Stratified by Therapeutic Target
For the group of patients within the therapeutic target (n = 514), differences were found in warfarin dose (mg/wk) and in INR/ current dose ratio according to amiodarone use (n = 57), even after adjustment (Table 2 ). For the group of patients not within the therapeutic target (n = 352), similar differences in variables were observed. Here, frequencies of adverse events, major or minor bleedings, and patients with INR ≥ 4 were not different between groups.
Analyses of Polymorphisms and Other Drugs with Simultaneous Use of Amiodarone
Mean warfarin dose was lower (25.0 ± 10.4 mg/wk) in EM patients on amiodarone (n = 74) compared with EM patients not on amiodarone (n = 561; 30.6 ± 13.8 mg/wk, P = 0.001). For IM + PM patients, those taking amiodarone (n = 37) had lower warfarin doses (21.1 ± 15.0 mg/wk) compared with those not taking amiodarone (n = 194, 27.0 ± 10.5 mg/wk, P < 0.01; Table 3 ).
Regarding the VKORC1 3673 polymorphism (wild-type genotype GG patients or GA + AA patients), the warfarin mean dose was lower in GG patients who simultaneously took amiodarone (26.8 ± 12.2 mg/wk, n = 59) compared with GG patients who did not take amiodarone (33.4 ± 13.2 mg/wk, n = 348, P < 0.001). For the GA + AA patients, findings were similar: 20.3 ± 10.9 mg/wk in patients taking amiodarone (n = 52) versus 26.4 ± 12.1 mg/wk in those not taking amiodarone (n = 407, P = 0.001; Table 3 ).
In our sample, use of omeprazole and/or a statin was very frequent. Thus, to exclude a possible influence, patients who took these drugs were excluded. The same difference was observed for the warfarin dose: 30.1 ± 15.4 mg/wk for patients who did not take amiodarone (n = 315) and 21.8 ± 11.1 mg/wk for patients who took amiodarone (n = 40, P = 0.001). The same finding was also observed regarding adverse events.
■■ Discussion
The main finding of this study was that the simultaneous use of amiodarone influences the warfarin maintenance dose, but it is not associated with an increased risk of adverse events in a large sample of patients on anticoagulation therapy from a tertiary cardiovascular center. The interaction between warfarin and amiodarone is known. This interaction is usually thought to be associated with an increased incidence of bleeding events and a more difficult anticoagulation process when the dose of warfarin is not adequately decreased.
Here, besides the observed effect on the warfarin dose (probably by metabolic inhibition of cytochrome P450 enzymes from amiodarone use), we identified a trend towards significant differences in the frequency of patients within the therapeutic target and, interestingly, no differences in adverse events. One possible explanation for the observed findings is that our study checked patients with at least 12 months on therapy and that 
TABLE 3
Warfarin Dose According to Simultaneous Use of Amiodarone and Studied Polymorphisms physicians tend to prescribe lower doses of warfarin when patients are simultaneously prescribed amiodarone to avoid bleedings. In the same way, the trend of lower frequency of patients within the therapeutic target identified in the group of patients on amiodarone may be partially explained by this precaution. Contrary to common belief, the adverse event rate with warfarin may not be more frequent with concomitant amiodarone use. Corroborating our findings, a study evaluating the relative risk of hemorrhage in warfarin-drug interaction scenarios reported that the risk of hemorrhage was indeed not greater with the concomitant use of warfarin and amiodarone. 12 Our observed rate of hemorrhagic events was 2.4% for major bleeding, which is similar to the rates reported in randomized controlled trials of warfarin therapy, which have ranged between 1% and 3%. [24] [25] [26] [27] In a population-based cohort study involving 125,195 older patients with atrial fibrillation, the observed rate of major bleeding was 3.8%, with the highest rate being within the first 30 days of warfarin therapy. 28 Our TTR values were also similar to studies developed in other tertiary hospitals (from 53.9% to 65.1%). [29] [30] [31] INR/current dose ratio was also significantly higher in the group of patients taking amiodarone compared with patients who did not take amiodarone. This ratio is a simple and logical way of expressing the variability of INR response to the different warfarin doses according to amiodarone use. Higher identified values for patients taking amiodarone mean that lower doses can achieve adequate INR or that higher doses can exceed the maximum value of target INR.
Regarding CYP2C9 and VKORC1 genotypes, our stratified analysis allowed us to show identical findings, excluding the known effect from genotypes. For this patient population, studied polymorphisms influenced the warfarin maintenance dose in an additive manner, and no significant interaction with amiodarone use was observed. Some studies, in addition to clinical and genetic data, have used drug information to implement calculators for a warfarin dose (algorithms), which are now widely available. [32] [33] [34] [35] Our result reaffirms previous studies, which showed that inclusion of drug data in algorithms can improve algorithm accuracy.
Limitations
Our study has some potential limitations. First, our patient sample was selected during chronic warfarin treatment; thus, our findings cannot be extrapolated to patients beginning anticoagulation therapy or patients in other clinical scenarios. Second, our study classified the therapeutic target as having at least 2 consecutive adequate INR values, including the current test. However, this classification is considered adequate in the literature for large studies focusing on the identification of patients on stable doses. 21, [32] [33] [34] [35] [36] ■■ Conclusions Simultaneous use of amiodarone influences the warfarin maintenance dose, but it is not associated with adverse events in chronic anticoagulation therapy. Furthermore, no significant interactions with known polymorphisms that modulate warfarin metabolism were identified for the amiodarone effect. This lack of interaction does not mean that one should initiate concomitant warfarin treatment with amiodarone without caution. Achieving the therapeutic target is harder, and especially in the first weeks of concomitant treatment, special care should be exercised. Taken together, these data point toward the need for prospective studies of the anticoagulation initiation period in patients using amiodarone and the possible genotype interaction with this drug combination at the initial phase.
